The efficacy of sorafenib administration prior to TACE against the patients with intermediate HCC refractory to TACE

Trial Profile

The efficacy of sorafenib administration prior to TACE against the patients with intermediate HCC refractory to TACE

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Jan 2014

At a glance

  • Drugs Sorafenib (Primary) ; Antineoplastics
  • Indications Liver cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Jan 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top